MIGMA
MIGMA helps companies find effective, safe, and cost-conscious antioxidant blends by combining computational search with laboratory validation. The company uses artificial intelligence and proprietary models to screen roughly 1.5×10^15 possible antioxidant combinations and propose candidate formulations tailored to client constraints like antioxidant power, maximum concentrations, and antioxidant class. MIGMA pairs in silico design with lab testing and offers services including model generation, data modeling, formulation licensing, patenting, and consulting. The platform operates as a B2B AI-driven formulation and R&D service for food, cosmetics, nutraceutical, and chemical companies seeking optimized antioxidant solutions.
MIGMA
MIGMA helps companies find effective, safe, and cost-conscious antioxidant blends by combining computational search with laboratory validation. The company uses artificial intelligence and proprietary models to screen roughly 1.5×10^15 possible antioxidant combinations and propose candidate formulations tailored to client constraints like antioxidant power, maximum concentrations, and antioxidant class. MIGMA pairs in silico design with lab testing and offers services including model generation, data modeling, formulation licensing, patenting, and consulting. The platform operates as a B2B AI-driven formulation and R&D service for food, cosmetics, nutraceutical, and chemical companies seeking optimized antioxidant solutions.
TL;DR
What they do: AI-driven discovery and lab validation of synergistic antioxidant formulations for food, cosmetics, nutraceuticals and chemicals
Founded: 2024
Headquarters: Dover, Delaware
Stage / funding: Pre-Seed (Dec 1, 2024) — investor: GRID EXPONENTIAL
Team size: 5 employees (reported)
Company Overview
Problem Domain
Formulation discovery and optimization for antioxidant solutions (shelf-life/stability enhancement).
Founded
2024
Industry
Biotechnology
Tech Stack
Funding Track Record
Investor Signal
“GRID EXPONENTIAL participated in Pre-Seed”